Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study-Reference-Cited by-同舟云学术

Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study

Published:2022-08 Issue: Volume:64 Page:103931
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Rolfes Leoni,Pfeuffer Steffen,Huntemann Niklas,Schmidt Mariella,Su Chuanxin,Skuljec Jelena,Aslan Derya,Hackert Jana,Kleinschnitz Konstanze,Hagenacker Tim,Pawlitzki Marc,Ruck Tobias,Kleinschnitz Christoph,Meuth Sven G.,Pul Refik

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference21 articles.

1. Immune reconstitution therapies: concepts for durable remission in multiple sclerosis;Lunemann;Nat. Rev. Neurol.,2020

2. Both cladribine and alemtuzumab may effect MS via B-cell depletion;Baker;Neurol. Neuroimmunol. Neuroinflamm.,2017

3. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis;Comi;Mult. Scler. Relat. Disord.,2019

4. Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers;Stuve;Ther. Adv. Neurol. Disord.,2019

5. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells;Ceronie;J. Neurol.,2018

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early clinical effect of cladribine in patients with highly active multiple sclerosis in Mexico;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2024-07

2. European flow cytometry quality assurance guidelines for the diagnosis of primary immune deficiencies and assessment of immune reconstitution following B cell depletion therapies and transplantation;Cytometry Part B: Clinical Cytometry;2024-06-28

3. Cladribine tablets in Relapsing-Remitting Multiple Sclerosis preferentially target B-cells;2024-03-29

4. Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop);European Journal of Neurology;2024-03-28

5. Sustained effects on immune cell subsets and autoreactivity in multiple sclerosis patients treated with oral cladribine;Frontiers in Immunology;2024-02-16